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BACKGROUND AND PURPOSE. 
Alpha 7 nicotinic acetylcholine receptors (α7-nAChRs) may represent useful targets for 
cognitive improvement. The aim of this study is to compare the procognitive activity of 
selective α7-nAChR ligands, including the partial agonists, DMXBA and A-582941, as well 
as the positive allosteric modulator, 3-furan-2-yl-N-p-tolyl-acrylamide (PAM-2).  
EXPERIMENTAL APPROACH 
The attentional set-shifting task (ASST) and the novel object recognition task (NORT) in rats, 
were used to evaluate the procognitive activity of each ligand [i.e., PAM-2 (0.5, 1.0, and 2.0 
mg·kg-1), DMXBA and A-582941 (0.3 and 1.0 mg·kg-1)], in the absence and presence of 
methyllycaconitine (MLA), a selective competitive antagonist. To determine potential drug 
interactions, an inactive dose of PAM-2 (0.5 mg·kg-1) was co-injected with inactive doses of 
either agonist [DMXBA: 0.1 (NORT) and 0.3 mg·kg-1 (ASST); A-582941: 0.1 mg·kg-1]. 
KEY RESULTS 
Our results reveal that PAM-2, DMXBA, and A-582941 improve cognition in a MLA-
dependent manner, indicating that the observed activities are mediated by α7 nAChRs. 
Interestingly, the co-injection of inactive doses of PAM-2 and DMXBA or A-582941 also 
improves cognition, suggesting drug interactions. Moreover, PAM-2 reversed the 
scopolamine-induced NORT deficit. The electrophysiological results also support the view 
that PAM-2 potentiates the α7 nAChR currents elicited by a fixed concentration (3 μM) of 
DMXBA with apparent EC50 = 34 ± 3 μM and Emax = 225 ± 5 %.  
CONCLUSIONS AND IMPLICATIONS 
Our results support the view that α7 nAChRs are involved in cognition processes and that 
PAM-2 is a novel promising candidate for the treatment of cognitive disorders.  
 
Abbreviations 
AChR, nicotinic acetylcholine receptor; AD, Alzheimer’s disease,; PAM, positive allosteric 
modulator; PAM-2, 3-furan-2-yl-N-p-tolyl-acrylamide; MLA, methyllycaconitine; ASST, 
attentional set-shifting task; SD, simple discrimination; CD, compound discrimination; Rev, 
reversal of discrimination; ID, intra-dimensional; ED, extra-dimensional; NORT, novel 
object recognition task; ITI, inter-trial interval; SCOP, scopolamine; T1, familiarisation trial; 
T2, retention trial; E, exploration time; DI, discrimination index; Emax, ligand efficacy; 
apparent EC50, enhancement potency; nH, Hill coefficient; r
2
, goodness of fit. 
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Introduction 
The α7 nicotinic acetylcholine receptor (AChR) is member of the Cys-loop ligand-gated ion 
channel family (receptor nomenclature follows Alexander et al. (2013a)). α7 AChRs are one 
of the most abundant subtypes expressed in brain areas (e.g., hippocampus, amygdala, 
midbrain, and prefrontal cortex) involved in important physiological functions such as 
memory, cognition, and different types of learning tasks (reviewed in (Freedman, 2014) ). 
Important roles in the development of neurological diseases with cognitive impairments such 
as Alzheimer’s disease (AD), schizophrenia, and Huntington’s disease, have been assigned to 
these AChRs as well. In this regard, a great effort has been made lately in the synthesis and 
functional characterization of selective α7 AChR ligands, including agonists, antagonists, and 
positive allosteric modulators (PAMs) (Arias et al., 2010;Tietje et al., 2008; reviewed in: 
Freedman, 2014;Pohanka, 2012; Arias, 2011) as attempts to develop treatment for these 
diseases. 
Allosteric modulation has been proposed as an advantageous therapeutic strategy compared 
to the orthosteric activation of α7 AChRs (Uteshev, 2014;Williams et al., 2011). The 
structural diversity of allosteric sites allows for greater receptor selectivity. Since PAMs do 
not directly activate AChRs the risk of overdosing is limited. Since PAMs do not compete 
with the agonist binding sites, this approach may be particularly beneficial in schizophrenic 
patients who usually smoke more tobacco than the general population. Furthermore, type II 
PAMs, which are less prone to cause prolonged α7 nAChR desensitisation and even 
reactivate desensitized nAChRs, do not produce the loss of function that may occur after the 
chronic administration of an agonist. 
Recently, a series of PAMs with selectivity for the α7 AChR has been synthesised and 
pharmacologically characterized (Arias et al., 2011). Among them, 3-furan-2-yl-N-p-tolyl-
acrylamide (PAM-2) presents antidepressant (Arias et al., 2015;Targowska-Duda et al., 
2014a), promnesic and anxiolytic (Targowska-Duda et al., 2014b), and antinociceptive and 
anti-inflammatory activity (Bagdas et al., 2015) in mice. To complete these preclinical 
studies, and to determine the procognitive activity of PAM- 2, two animal tests, namely the 
attentional set-shifting task (ASST) (Nikiforuk et al., 2010) and the novel object recognition 
task (NORT) (Nikiforuk et al., 2013), were used on male rats. 
The ASST is a rodent version of the Intra/Extra Dimensional set-shifting task (Roberts et al., 
1988) that assesses cognitive flexibility (i.e., the ability to modify behaviour in response to 
the altering relevance of stimuli). In this paradigm, rats must select a bowl containing a food 
reward based on the ability to discriminate the odours or the media covering the bait (Birrell 
& Brown, 2000). The ASST requires rats to initially learn a rule and form an attentional “set” 
within the same stimulus dimensions. At the extra-dimensional (ED) shift stage, the essential 
phase of the task, animals must switch their attention to a previously irrelevant stimulus 
dimension and, for example, discriminate between the odours and not between the media 
covering the bait. The animal’s performance at the ED stage is considered an index of 
cognitive flexibility and depends on the medial prefrontal cortex (mPFC) (Birrell & Brown, 
2000).  
The NORT in rodents has been increasingly used as an ethologically relevant paradigm for 
studying visual episodic memory (Ennaceur & Delacour, 1988). This task is based on the 
spontaneous exploration of novel and familiar objects. Successful object recognition is 
displayed by more time spent interacting with the novel object in the retention trial. 
Introducing longer inter-trial intervals (e.g., 24 h in the present experiments) abolishes object 
discrimination. This delay-induced deficit closely resembles natural forgetting.  
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The procognitive activity elicited by PAM-2 was compared to that for two partial agonists 
with selectivity for the α7 AChR, namely DMXBA (also named GTS-21) (reviewed in 
(Freedman, 2014) and A-582941 (Tietje et al., 2008), and the observed drug activities 
challenged by the selective competitive antagonist, methyllycaconitine (MLA) (Arias et al., 
2010). To determine whether drug interactions occur, the combination of drugs at inactive 
doses was also tested. Moreover, the ability of PAM-2 to ameliorate the scopolamine-induced 
object recognition deficit was assessed. Finally, electrophysiological experiments using SH-
SY5Y-7 cells were performed to determine the potentiation of DMXBA-evoked α7 nAChR 
currents elicited by PAM-2. 
 
Materials and Methods  
Animals 
Male Sprague-Dawley rats (Charles River, Germany), weighing 200-250 g on arrival, were 
housed in a temperature-controlled (21 ± 1 °C) and humidity-controlled (40–50%) colony 
room under a 12 h/12 h light/dark cycle (lights on at 06:00 am). For the ASST experiments, 
rats were individually housed with a mild food restriction (17 g of food pellets per day) for at 
least one week prior to testing. For the NORT studies, rats were group-housed (5 rats/cage) 
with free access to food and water. Behavioural testing was performed during the light phase 
of the light/dark cycle. The experiments were conducted in accordance with the NIH Guide 
for the Care and Use of Laboratory Animals and were approved by the Ethics Committee for 
Animal Experiments, Institute of Pharmacology (Krakow, Poland). 
Attentional set-shifting task 
A detailed description of the apparatus and procedure has been provided previously 
(Nikiforuk et al., 2010). Briefly, rats were presented with two ceramic pots, with only one pot 
baited with a food reward (Honey Nut Cheerio, Nestle®). Animals had to retrieve the 
Cheerio on the basis on their ability to discriminate the odours associated with the pot and the 
digging media that covered Cheerio bait in the pot.  
The procedure entailed three days for each rat: habituation, training and testing. During a 
single test session, rats performed a series of 7 discriminations. In the simple discrimination 
involving only one stimulus dimension, the pots differed along one of two dimensions (e.g., 
digging medium). For the compound discrimination (CD), the second (irrelevant) dimension 
(i.e., odour) was introduced but the correct and incorrect exemplars of the relevant dimension 
remained constant. For the reversal of this discrimination (Rev 1), the exemplars and relevant 
dimension were unchanged but the previously correct exemplar was now incorrect and vice 
versa. The intra-dimensional (ID) shift was then presented, consisting of new exemplars of 
both the relevant and irrelevant dimensions with the relevant dimension remaining the same 
as previously. The ID discrimination was then reversed (Rev 2) so that the formerly positive 
exemplar became the negative one. This series of discriminations serves to progressively 
form an attentional set. For the extra-dimensional (ED) shift, a new pair of exemplars was 
again introduced, but this time a relevant dimension was also changed. At this essential phase 
of the task, animals must switch their attention to a previously irrelevant stimulus dimension 
and, for example, discriminate between the odours and not between the media covering the 
bait. Finally, the last phase was the reversal (Rev 3) of the ED discrimination. The first four 
trials at the beginning of each discrimination phase were a discovery period (not included in 
six trials to criteria). In subsequent trials, an incorrect choice was recorded as an error.  
Total number of animals used was N=198. All animals were tested once. 
  
This article is protected by copyright. All rights reserved. 
Novel object recognition task 
Apparatus. Rats were tested in a dimly lit (25 Lux) open field made of dull grey plastic 
(length x width x height: 66 x 56 x 30 cm).  
Procedure. Rats were habituated to the arena (without any objects) for 5 min 24 h before 
testing (Nikiforuk et al., 2013). The test consisted of two 3-min trials separated by an inter-
trial interval (ITI) of 24 h (or 60 min in the scopolamine study). During the first trial 
(familiarisation, T1), two identical objects (A1 and A2) were presented in opposite corners, 
approximately 10 cm from the walls of the open field. In the second trial (retention, T2), one 
of the objects was replaced by a novel one (A = familiar, and B = novel). The objects used 
were a glass bulb filled with gravel and a plastic bottle filled with sand. The height of the 
objects was comparable (~12 cm), and they were heavy enough to not be displaced by the 
animals. Half of the animals from each group received the glass bulb as a novel object, and 
the other half received the plastic bottle. The location of the novel object in the recognition 
trial was randomly assigned for each rat. Exploration of an object was defined by looking, 
licking, sniffing or touching the object while sniffing but not leaning against, standing or 
sitting on the object. Any rat that spent less than 5 s exploring the two objects within 3 min of 
T1 or T2 was eliminated from the study. The behaviour was recorded by the camera placed 
above the arena, and connected to the Any-maze® tracking system (Stoelting Co., Illinois, 
USA), which measured automatically the distance travelled by an animal. The experimenter 
manually assessed exploratory activity of animals. Based on the exploration time (E) of the 
two objects in the retention trial, a discrimination index (DI) was calculated as (EB–
EA)/(EA+EB).  
Total number of animals used was N=180. Each rat was tested twice, with a 7-day washout 
period between each of two tests. No animal received the same treatment twice. 
 
Drugs 
PAM-2, synthesised as in Bagdas et al (2015), was suspended in 1% Tween 80 (Sigma–
Aldrich, Poznan, Poland) in saline solution, whereas A-582941, DMXBA (GTS-21) (Tocris, 
Bristol, UK) and scopolamine (Sigma–Aldrich, Poznan, Poland) were dissolved in distilled 
water. Methyllycaconitine citrate (MLA) (Ascent Scientific, Bristol, UK) was dissolved in 
distilled water, and the solution was neutralised with 0.1 N NaOH. Drugs or vehicle 
(physiological saline) were administered in a volume of 1 mL·kg-1 of body weight. Fetal 
bovine serum (FBS) and trypsin/EDTA were purchased from Gibco BRL (Paisley, UK). 
Geneticin and neomycin were obtained from Tocris Bioscience (Ellisville, MO, USA). Salts 
were of analytical grade. The drug/molecular target nomenclature used in this manuscript 
conforms to British Journal of Pharmacology's Concise Guide to PHARMACOLOGY 
(Alexander et al., 2013b). 
Drug administration 
DMXBA (0, 0.3 or 1.0 mg·kg-1), A-582941 (0, 0.3 or 1.0 mg·kg-1) or PAM-2 (0, 0.5 or 1.0 
mg·kg-1 for the ASST, and 0, 1.0 or 2.0 mg·kg-1 for the NORT) were administered 
intraperitoneally (IP) 30 min before testing, i.e. the acquisition trial (T1) of the NORT or first 
discrimination stage of the ASST. To determine receptor selectivity, DMXBA (0 or 1.0 
mg·kg-1) and PAM-2 (0 or 1.0 mg·kg-1 for the ASST, and 0 or 2.0 mg·kg-1 for the NORT) 
were administered with MLA (0 or 3.0 mg·kg-1, IP) 30 min before testing. In the case of A-
582941, rats received MLA (0 or 3.0 mg·kg-1, IP) 30 min before the injection of the agonist 
(0 or 1.0 mg·kg-1), and after additional 30 min, the test was performed.  
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For the drug interaction study, rats were simultaneously injected with inactive doses of PAM-
2 (0 or 0.5 mg·kg-1) and DMXBA (0 or 0.3 mg·kg-1 for the ASST and 0 or 0.1 mg·kg-1 for the 
NORT) or/and A-582941 (0 or 0.1 mg·kg-1) 30 min prior to testing. To determine receptor 
selectivity, MLA (3.0 mg·kg-1) was administered with DMXBA and PAM-2 and after 
additional 30 min, the test was performed. In the case of A-582941, rats received MLA (3.0 
mg·kg-1) 30 min before the co-injection of the agonist and PAM-2. In the scopolamine study, 
PAM-2 (1.0 and 2.0 mg·kg-1) was administrated IP, followed 30 min later by IP 
administration of scopolamine 1.25 mg·kg-1, and after additional 30 min, the test was 
performed. 
Previous in vivo studies indicate that the IP administration of 1 μmol·kg-1 (~0.3 mg·kg-1) of 
A-582941 produces a maximal concentration of 300 ng/g (~1 μM) in the brain, which is 
enough to activate α7 AChRs (Tietje et al., 2008). The oral administration of DMXBA at a 
dose of 10 mg·kg-1 produces a peak concentration of 664 ng/g (>2 μM) in the brain (Mahnir 
et al., 1998). The IP administration of 6.2 μmol·kg-1 of MLA produces maximal brain levels 
of ~50-100 nM, which is enough to inhibit α7 AChRs (Turek et al., 1995). In addition, our 
initial pharmacokinetics experiments indicate that a brain concentration of ~0.2 μM of PAM-
2 is attained after the acute injection of 1.0 mg·kg-1 of the compound (unpublished results), 
which is enough to modulate α7 AChRs. 
 
Statistical analysis  
ASST. The number of trials required to achieve the criterion of 6 consecutive correct 
responses was recorded for each rat and for each discrimination phase of the ASST. Data 
presented in Figures 1a-c and Figures 5a-b were calculated using two-way mixed-design 
ANOVAs with the treatment as a between-subject factor and the discrimination phase as a 
repeated measure. For the antagonist studies (Figs. 3a-c), data were analysed using three-way 
mixed-design ANOVAs with MLA and the respective drug treatment as between-subject 
factors and the discrimination phase as a repeated measure.   
NORT. Data on exploratory preference were analysed using two-way (or three-way for the 
MLA studies) mixed-design ANOVAs with the respective drug treatment as between-subject 
factors and the object as a repeated measure. DI data were analysed by one-way (or two-way 
for the MLA studies) ANOVAs. Since the analyses of exploration time during retention trial 
(T2) and DI yielded the same results, only DI data were presented. Distance travelled was 
analysed using mixed-design ANOVAs (two- or three-way for the MLA studies) with the 
respective drug treatments as between-subject factors and trial as a repeated measure. Since 
there were no significant differences in the time spent exploring two identical objects in the 
acquisition phase in any drug-treated group and no significant treatment effects on the 
distance travelled by rats in the familiarisation and retention trials, these data are not 
presented. 
Post hoc comparisons were performed using the Newman-Keuls test. The α-value was set at 
P<0.05 level. The data fulfilled criteria of normal distribution. Statistical analyses were 
performed with the use of Statistica 10.0 for Windows.   
Electrophysiological measurements in SH-SY5Y-7 cells  
The human neuroblastoma SH-SY5Y cells were first stably transfected with the human 7 
subunit expression plasmid using the SuperFect kit (Quiagen, Hilden, Germany) according to 
the manufacturer’s instruction. Neomycin selection was initiated 48 h after transfection with 
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0.3 mg·ml-1 and reduced to 0.1 mg·ml-1 after appearance of single clones. About 10 SH-
SY5Y cell clones from this transfection showed specific 
125
I-α-bungarotoxin binding of 
>70%.   
The SH-SY5Y-7 cells overexpressing the 7 AChR were cultured as described in Arias et 
al. (2011). More precisely, the cells were cultured in Dulbecco’s Modified Eagle’s Medium 
supplemented with 10% (v/v) FBS and 100 µg ml-1 geneticin. The cells were cultured at 37 
°C, 5% CO2 and 95% relative humidity, and passaged every 3 days by detaching the cells 
from the cell culture flask by washing with phosphate-buffered saline and brief incubation 
(~3 min) with trypsin (0.5 mg·ml-1)/EDTA (0.2 mg·ml-1). 
The patch-clamp recordings were subsequently performed at room temperature in the whole-
cell configuration. During the experiments the cells were continuously perfused at 5 mL/min 
with standard solution (i.e., 145 mM NaCl, 5 mM KCl, 1 mM CaCl2, 5 mM HEPES, 5 mM 
glucose, and 20 mM sucrose, the pH was adjusted to 7.4 with NaOH). Patch electrodes had a 
resistance of 3-5 MΩ and were filled with 140 mM KCl, 5 mM HEPES, 5 mM EGTA, 3 mM 
MgCl2, and 2 mM Na2ATP (the pH was adjusted to 7.2 with KOH). Cells were voltage 
clamped at -60 mV and access resistance was monitored throughout the recordings. Currents 
were amplified with an Axopatch 1D amplifier, filtered at 5 kHz, and digitized at 10 kHz. 
Drugs were applied directly by gravity through a Y-tube perfusion system. Drug application 
had a fast onset and achieved a complete local perfusion of the recorded cell. Application of 3 
μM DMXBA produced a current characterized by a peak and its concomitant plateau that is 
reached after few milliseconds. Subsequently, the agonist and different concentrations of 
PAM-2 (i.e., 1-300 μM) were applied, producing larger currents.  
The concentration-potentiation relationship for PAM-2 was determined by using non-linear 
regression (GraphPad-Prism software, CA, USA), by fitting the experimental data into the 
modified Hill equation:  
IPAM-2 / IDMXBA = 1 / [1 + (apparent EC50/[PAM-2])
nH]                      (1)  
where IDMXBA is the response to 3 μM DMXBA, IPAM-2 is the response to 3 μM DMXBA in 
the presence of different concentrations of PAM-2 (i.e., [PAM-2]), apparent EC50 is the 
concentration of PAM-2 producing half-maximal potentiation, and nH is the Hill coefficient. 
 
Results 
The procognitive effects of DMXBA, A-582941 and PAM-2.  
Attentional set-shifting task  
Two-way mixed-design ANOVAs revealed significant interactions between the 
discrimination phase and respective drug treatment: F[12,90]=22.39, p<0.001 (DMXBA, Fig. 
1a), F[12,90]=6.01, p<0.001 (A-582941, Fig. 1b) and F[12,90]=13.99, p<0.001 (PAM-2, Fig. 
1c). 
Pos-hoc analysis revealed that the acute administration of DMXBA (1.0 mg·kg-1, Fig. 1a), A-
582941 (0.3 and 1.0 mg·kg-1, Fig. 1b), and PAM-2 (1.0 mg·kg-1, Fig. 1c) significantly and 
specifically enhanced rats’ cognitive flexibility, as indicated by a reduced number of trials to 
criterion during the ED stage of the ASST. There was no significant drug effect during any 
other discrimination stage.  
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Novel object recognition task 
In the retention trial, vehicle-treated rats did not discriminate the novel object from the 
familiar one and this time-induced natural forgetting was ameliorated by DMXBA (Fig. 2a), 
A-582941 (Fig. 2b), and PAM-2 (Fig. 2c). Accordingly, one-way ANOVAs revealed a 
significant effect of drug treatment on the DI measures: F[2,24]=10.85, p<0.001 (DMXBA, 
Fig. 2a), F[2,24]=14.71, p<0.001 (A-582941, Fig. 2b), and F[2,24]=16.38, p<0.001 (PAM-2, 
Fig. 2c). Post hoc analyses demonstrated that DMXBA (0.3 and 1.0 mg·kg-1, Fig. 2a), A-
582941 (0.3 and 1.0 mg·kg-1, Fig. 2b), and PAM-2 (1.0 and 2.0 mg·kg-1, Fig. 2c) significantly 
increased DI compared to the controls.   
The α7 nAChR antagonist, methyllycaconitine, reverses the procognitive effects of 
DMXBA, A-582941, and PAM-2. 
Attentional set-shifting task 
The selective α7 nAChR antagonist, MLA (3.0 mg·kg-1), blocked the procognitive effects of 
active doses of DMXBA (1.0 mg·kg-1, Fig. 3a), A-582941 (1.0 mg·kg-1, Fig. 3b), and PAM-2 
(1.0 mg·kg-1, Fig. 3c). However, MLA did not affect performance at any of the ASST stages 
when co-administered with a vehicle. Three-way mixed-design ANOVAs revealed significant 
interactions among the discrimination phase, MLA and the respective drug treatment: 
F[6,120]=14.91, p<0.001 (DMXBA, Fig. 3a), F[6,120]=12.56, p<0.001 (A-582941, Fig. 3b), 
and F[6,120]=12.56, p<0.001 (PAM-2, Fig. 3c). 
Novel object recognition task 
As shown in Figure 4a-c, the DI in rats co-treated with MLA (3.0 mg·kg-1) and either 
DMXBA (1.0 mg·kg-1), A-582941 (1.0 mg·kg-1), or PAM-2 (2.0 mg·kg-1) was significantly 
lower than that in groups treated with the respective compound alone. Thus, MLA blocked 
the procognitive effects of the tested compounds. Two-way ANOVA interactions between 
MLA and the respective drug treatment revealed the following results: F[1,34]=7.14, p<0.05 
(DMXBA, Fig. 4a), F[1,34]=21.19, p<0.001 (A-582941, Fig. 4b), and F[1,34]=11.42, 
p<0.01, (PAM-2, Fig. 4c). 
The co-administration of inactive doses of PAM-2 with either DMXBA or A-582941 
facilitates cognitive performance. 
Attentional set-shifting task 
The co-administration of inactive doses of PAM-2 (0.5 mg·kg-1) with either DMXBA (0.3 
mg·kg-1; Fig. 5a) or A-582941 (0.1 mg·kg-1; Fig. 5b) to rats reduced the number of trials to 
criterion in the ED phase as compared to the vehicle/vehicle-treated group and to the 
vehicle/DMXBA- (Fig. 5a) or vehicle/A-582941-treated (Fig. 5b) groups. The procognitive 
effects of the drug combinations were blocked by MLA (Figs. 5a-b), indicating that the 
observed effects are α7 nAChR-dependent.  
Novel object recognition task. 
The co-administration of inactive doses of PAM-2 (0.5 mg·kg-1) with either DMXBA (0.1 
mg·kg-1, Fig. 6a) or A-582941 (0.1 mg·kg-1, Fig. 6b) augmented the rats’ ability to 
discriminate the novel object from the familiar object in the retention trial. The DI in rats co-
treated with PAM-2 and either DMXBA (F[5,54]=9.31, p<0.001, Fig. 6a) or A-582941 
(F[5,54]=25.35, p<0.001, Fig. 6b) was significantly higher than that for the vehicle-treated 
(control) and drug (alone)-treated rats. Interestingly, MLA (3.0 mg·kg-1) blocked the 
procognitive effects of the drug combinations (Figs. 6a-b). 
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PAM-2 reverses the scopolamine-induced object recognition deficit.  
As demonstrated in Figure 7, the administration of scopolamine abolished the ability to 
discriminate novel and familiar objects (one-way ANOVA: F[3.36]=18.41, p<0.001). PAM-2 
(1.0 and 2.0 mg·kg-1) significantly attenuated the observed scopolamine-induced DI 
reduction. 
PAM-2 enhances the α7 nAChR activity elicited by DMXBA. 
The electrophysiological results indicated that PAM-2 enhances the activity elicited by a 
fixed concentration (3 μM) of DMXBA, a selective α7 nAChR partial agonist (Fig. 8).  The 
observed plateau current elicited by 3 μM DMXBA on α7 nAChRs was considered the 
control value (IDMXBA). Increasing concentrations of PAM-2 (i.e., 1-300 μM) potentiated the 
initial current (IPAM-2), reaching an Emax value of 225 ± 5 %. This value is practically the same 
as that determined by Ca
2+
 influx experiments (204 ± 13 %), where (±)-epibatidine was used 
as the agonist (Arias et al., 2011). The concentration-response curve gave an apparent 
potentiating EC50 value of 34 ± 3 μM, which is larger than that determined previously by 
Ca
2+
 influx assays (~5 μM; (Arias et al., 2011). Several possible causes might account for 
this difference: (1) methodological differences between the used electrophysiological (this 
paper) and Ca
2+
 influx (Arias et al., 2011) techniques, (2) the use of different cell types: 
GH3-α7 cells for the Ca2+ influx assays (Arias et al., 2011) vs. the SH-SY5Y-7 cells for this 
study, (3) the use of a very low initial concentration of (±)-epibatidine (EC5 = 20 nM) for the 
Ca
2+
 influx experiments (Arias et al., 2011) compared to the used concentration of DMXBA 
(3 μM) which corresponds approximately to its EC25 value (Papke & Porter Papke, 2002). 
This possibility is supported by the fact that at a higher concentration of DMXBA (10 μM), 
the potentiation elicited by 100 μM PAM-2 was 175 ± 28 % (n = 4), a value slightly lower 
than that using 3 μM DMXBA (i.e., 212 ± 20 %; see Fig. 8), and finally, (3) that the used 
PAM-2 was synthetized by a new method which rends molecules with slightly less activity 
(Bagdas et al., 2015). On the other hand, the fact that the calculated nH value (1.71 ± 0.23) is 
higher than unity suggests cooperative interactions for PAM-2, as was described previously 
(Arias et al., 2011;Bagdas et al., 2015). 
 
Discussion 
The present study demonstrate that PAM-2, a selective α7 nAChR PAM, as well as DMXBA 
and A-582941, selective α7 nAChR agonists, facilitate cognitive flexibility, as assessed by 
the ASST, and attenuate the delay-induced impairment in NORT performance in rats. Since 
MLA, a selective α7 nAChR competitive antagonist, fully blocked the procognitive effects 
mediated by the tested compounds, we inferred that the observed activities are mediated by 
α7 nAChRs. Interestingly, the co-injection of inactive doses of PAM-2 and DMXBA or A-
582941 also improved rats’ performance on the ASST and NORT in a MLA-dependent 
manner, suggesting agonist-PAM synergism.  
The observed effects of α7 nAChR ligands in the ASST corroborate previous results 
suggesting an involvement of the nicotinic receptor system in processes underlying cognitive 
flexibility. Accordingly, Allison and Shoahib (2013) demonstrated that either sub-chronic or 
acute administration of nicotine improves rat performance on the ASST. Although α7-/- mice 
did not demonstrate impaired performance on the ASST (Young et al., 2011), recent 
preclinical data suggest that an approach based on α7 nAChR stimulation may be useful in 
treating schizophrenia-like cognitive inflexibility in the neurodevelopmental or NMDA 
receptor blockade-based model. Likewise, acute administration of RG3487 and SSR180711, 
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α7 nAChR partial agonists, reversed ED deficits in rats sub-chronically treated with the 
NMDA receptor antagonist, phencyclidine (Wallace et al., 2011), and in rats with transient 
inactivation of the neonatal ventral hippocampus (Brooks et al., 2012), respectively. 
DMXBA, used in our experiments, has been also demonstrated to be effective in alleviating 
dizocilpine-evoked deficits in a rat maze-based strategy set-shifting paradigm (Jones et al., 
2014). However, the active dose of DMXBA was much higher (i.e., 30 mg·kg-1) than that 
used in the current experiments (i.e., 1.0 mg·kg-1). This discrepancy may arise from 
differences in the applied paradigm (perceptual vs strategy set shifting) or in the testing 
condition (cognitively unimpaired vs impaired animals). In addition, such high doses may 
produce enough endogenous concentrations to inhibit non-α7 AChRs. To our knowledge, A-
582941 has not been evaluated in any set-shifting procedure. 
Less is known about the effects of α7 nAChR PAMs on set-shifting performance, and the 
only published data in this regard concern to PNU-120596. This type II α7-selective PAM 
was effective in reversing sub-chronic phencyclidine-induced ED set-shifting deficits on the 
ASST (McLean et al., 2012). Hence, our study supports the involvement of α7 nAChRs in 
the modulation of cognitive flexibility by demonstrating that selective agonists, DMXBA and 
A-582941, as well as PAM-2, a selective α7-PAM, facilitate set-shifting performance in 
cognitively unimpaired control rats. These effects were blocked by MLA, a selective α7 
nAChR competitive antagonist, supporting the notion that the observed drug activities are 
mediated by α7 nAChRs. However, a direct comparison of our findings to other studies is not 
possible because most of the previous experiments did not include α7 nAChR agonist-treated 
control rats (Jones et al., 2014;McLean et al., 2012;Wallace et al., 2011). Since relatively 
high levels of performance were achieved in those studies (Brooks et al., 2012), further 
improvement could not be accomplished. 
Our results also demonstrated that the efficacy of PAM-2 to enhance rats’ object recognition 
memory is comparable to those mediated by the partial agonists, DMXBA and A-582941. 
The effectiveness of α7 nAChR agonists has been widely documented in NORT studies 
(Lyon et al., 2012). In line with our data, Callahan et al. (2014) demonstrated that DMXBA 
(1-10 mg·kg-1) enhanced rats’ object recognition memory at the 48 h delay and that this effect 
was antagonised by MLA in a dose-dependent manner (1.25 and 5 mg·kg-1). Moreover, A-
582941 (at doses <0.3 mg·kg-1) improved recognition memory in the social discrimination 
task in rats (Bitner et al., 2007).  
Although α7 nAChR PAMs have been demonstrated to be effective against the 
pharmacologically induced deficits of object recognition (Pandya & Yakel, 2013;Eskildsen et 
al., 2014), the restoration of delay-induced forgetting by this class of compounds has not 
been demonstrated. In contrast to the effectiveness of PAM-2 in alleviating spontaneous 
forgetting, Callahan et al. (2013) showed that PNU-120596 did not have a significant effect 
on Sprague-Dawley rats’ NORT performance when tested with a 48 h delay. However, the 
combination of PNU-120596 with a subthreshold dose of donepezil, an acetylcholinesterase 
inhibitor used for the treatment of AD, reversed delay-induced forgetting in that task 
(Callahan et al., 2013). 
Our result also demonstrated that PAM-2 reversed object recognition impairment induced by 
scopolamine, a pharmacological model of cholinergic deficits known to be associated with 
AD. These results are corroborated by the previous study demonstrating that PAM-2 was also 
effective against the scopolamine-induced impairment in the passive avoidance test in mice 
(Targowska-Duda et al., 2014b). In line with these data, PNU-120596 restored object 
recognition memory in scopolamine treated rats (Pandya & Yakel, 2013), and another α7 
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nAChR PAM, NS-1738, reversed scopolamine-induced deficits in the Morris water maze 
task in rats (Timmermann et al., 2007). Several studies demonstrated the efficacies of α7 
nAChR agonists against AD-like pathology. For example, DMXB ameliorated the spatial 
memory deficits induced by intracerebroventricular injection of β-amyloid25–35 to mice 
(Chen et al., 2010). Moreover, A-582941 restored learning and memory in aged 3xTg-AD 
mice with robust AD-like pathology (Medeiros et al., 2014). Determining the efficacy of α7 
nAChR PAMs awaits further studies. 
The electrophysiological results indicated that PAM-2 potentiates DMXBA-evoked α7 
nAChR activity. Studies in hippocampal interneurons demonstrated that either PAM-2 (Arias, 
submitted paper) or PNU-120596 (Lopez-Hernandez et al., 2009) potentiates the activity of 
4OH-DMXBA, an active DMXBA metabolite with selectivity for the α7 nAChR. These 
results fit very well with our behavioural results showing that the co-administration of an 
inactive dose of PAM-2 with either DMXBA or A-582941 enhanced cognitive flexibility and 
recognition memory in rats in a MLA-dependent manner. Our results in the NOR test, in turn, 
are in agreement with studies using passive avoidance tests, showing that PAM-2 improves 
memory consolidation and that nicotine potentiates the promnesic activity elicited by PAM-2 
(Targowska-Duda et al., 2014b). Taking together, these results support the view that the 
procognitive and promnesic activity elicited by PAM-2 alone or in combination with agonists 
are mediated by α7 nAChRs. 
One may notice that the dose response-relationship to PAM-2 is very steep. A similar trend 
was observed for the activity of PAM-2 on memory acquisition determined by the passive 
avoidance test (Targowska-Duda et al., 2014b). More precisely, 1.0, but not 0.5, mg·kg-1 of 
PAM-2 increased memory acquisition. Likewise, another α7 nAChR PAM, CCMI, exerted 
procognitive effects at a dose of 1 mg·kg-1 but was inactive when administered at a dose of 
0.3 mg·kg-1 (Nikiforuk et al., 2015). Nevertheless, the dose of 0.5 mg·kg-1 PAM-2 was 
effective when co-administered with α7 nAChR agonists. A possibility is that the attained 
brain concentration at 0.5 mg·kg-1 PAM-2 is not enough to modulate endogenous ACh-
activated α7 AChRs. Alternatively, the cognitive-enhancing effects of a lower dose of PAM-
2 may be revealed in cognitively-impaired animals, in which the level of performance is low 
enough to allow for further improvement. 
A wide body of evidence suggests that α7 nAChRs are involved in the modulation of the 
release of a number of neurotransmitters that have been implicated in cognitive functions 
such as glutamate, GABA, and dopamine (Bencherif et al., 2012). Alternatively, stimulation 
of α7 nAChRs may activate signalling pathways known to be involved in cognitive functions. 
For example, Bitner et al. (2007) demonstrated that the procognitive efficacy of A-582941 
correlates with increases in extracellular-signal regulated kinase 1/2 (ERK1/2) and cAMP 
response element-binding protein (CREB) phosphorylation. Interestingly, the chronic 
treatment with 0.5 mg·kg-1 PAM-2 also increases ERK1/2 phosphorylation in the mouse 
hippocampus, a brain area involved in memory and cognition (paper in preparation).  
The present study demonstrates the role of α7 nAChRs on recognition memory and cognitive 
flexibility in rat preclinical tasks, as well as the ability of α7 nAChR ligands to enhance these 
important functions. The procognitive efficacy of PAM-2 is comparable to those of 
orthosteric agonists. Thus, PAM-2, alone or in combination with lower doses of selective 
agonists, likely represents a useful pharmacological approach for cognitive enhancement. The 
compound’s efficacy against disease-like cognitive impairments awaits further studies. 
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Fig. 1: DMXBA (a), A-582941 (b), and PAM-2 (c) improve attentional set-shifting. 
DMXBA (0, 0.3 or 1.0 mg·kg-1), A-582941 (0, 0.3 or 1.0 mg·kg-1), or PAM-2 (0, 0.5 or 1.0 
mg·kg-1) was administrated IP 30 min before testing. The results represent the mean ± S.E.M. 
of a number of trials required to reach the criterion of 6 consecutive correct trials for each of 
the discrimination phases i.e., simple discrimination (SD), compound discrimination (CD), 
reversal 1 (Rev1), intradimensional shift (ID), reversal 2 (Rev 2), extradimensional shift (ED) 
and reversal 3 (Rev 3). N = 6 rats per group. ***p<0.001 and **p<0.01, significant 
improvement in ED performance compared to that for the vehicle-treated group. 
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Fig. 2: DMXBA (a), A-582941 (b), and PAM-2 (c) improve novel object recognition. 
DMXBA (0, 0.3 or 1.0 mg·kg-1), A-582941 (0, 0.3 or 1.0 mg·kg-1), or PAM-2 (0, 1.0 or 2.0 
mg·kg-1) was administrated IP 30 min before T1 (acquisition trial). T2 (retention trial) was 
performed 24 h after T1. Data are shown as the mean ± S.E.M. of discrimination index (DI) 
during T2. N = 7-10 rats per group. ***p<0.001, **p<0.01, and *p<0.05, significant increase 
in DI compared to that for the vehicle-treated group. 
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Fig. 3: Methyllycaconitine reverses the facilitation of attentional set-shifting elicited by DMXBA 
(a), A-582941 (b), and PAM-2 (c). 
Methyllycaconitine (MLA; 0 or 3.0 mg·kg-1, IP) was co-administered with DMXBA (0 or 1.0 mg·kg-1, 
IP), A-582941 (0 or 1.0 mg·kg-1, IP), or PAM-2 (0 or 1.0 mg·kg-1, IP), 30 min before testing. The 
results represent the mean ± S.E.M. number of trials required to reach the criterion of 6 consecutive 
correct trials for each of the discrimination phases i.e., simple discrimination (SD), compound 
discrimination (CD), reversal 1 (Rev1), intradimensional shift (ID), reversal 2 (Rev 2), 
extradimensional shift (ED) and reversal 3 (Rev 3). N = 6 rats per group. ***p<0.001, significant 
improvement in ED performance compared to that for the vehicle-treated group. ###p<0.001, 
significant reduction in ED performance compared to that for the DMXBA (a)-, A-582941 (b)-, or 
PAM-2 (c)-treated group. 
  
This article is protected by copyright. All rights reserved. 
 
Fig. 4 Methyllycaconitine reverses the improvement of novel object recognition elicited 
by DMXBA (a), A-582941 (b), and PAM-2 (c). 
Methyllycaconitine (MLA; 0 or 3.0 mg·kg-1, IP) was co-administered with DMXBA (0 or 1.0 
mg·kg-1, IP), A-582941 (0 or 1.0 mg·kg-1, IP), or PAM-2 (0 or 2.0 mg·kg-1, IP) 30 min before 
T1 (acquisition trial). T2 (retention trial) was performed 24 h after T1. Data are shown as the 
mean ± S.E.M of discrimination index (DI) during T2. N = 9-10 rats per group. ***p<0.001, 
significant increase in DI compared to that for the vehicle-treated group. ###p<0.001, 
significant reduction in DI compared to that for the DMXBA (a)-, A-58294 (b)-, or PAM-2 
(c)-treated group. 
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Fig. 5: The co-administration of inactive doses of PAM-2 with either DMXBA (a) or A-
582941 (b) facilitates attentional set-shifting. 
PAM-2 (0 or 0.5 mg·kg-1) was co-injected with DMXBA (0 or 0.3 mg·kg-1) or A-582941 (0 
or 0.1 mg·kg-1) 30 min before testing. Results represent the mean ± S.E.M. of a number of 
trials required to reach the criterion of 6 consecutive correct trials for each of the 
discrimination phases, i.e., simple discrimination (SD), compound discrimination (CD), 
reversal 1 (Rev1), intradimensional shift (ID), reversal 2 (Rev 2), extradimensional shift (ED) 
and reversal 3 (Rev 3). N = 6 rats per group. ***p<0.001, significant improvement in ED 
performance compared to that for the vehicle/vehicle-treated group. ###p<0.001, significant 
improvement in ED performance compared to that for the vehicle+DMXBA (a)- and 
vehicle+A-582941 (b)-treated group. +++p<0.001, significant reduction in ED performance 
compared to that for the PAM-2+DMXBA (a)- or PAM-2+A-58294 (b)-treated group.   
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Fig. 6: The co-administration of inactive doses of PAM-2 with either DMXBA (a) or A-
582941 (b) facilitates novel object recognition memory. 
PAM-2 (0 or 0.5 mg·kg-1) was co-injected with DMXBA (0 or 0.1 mg·kg-1) or A-582941 (0 
or 0.1 mg·kg-1) 30 min before T1 (acquisition trial). T2 (retention trial) was performed 24 h 
after T1. Data are shown as the mean ± S.E.M. of discrimination index (DI) during T2. 
Symbols: ***p<0.001 significant increase in DI compared to that for the vehicle-treated 
group; ###p<0.001 significant increase in DI compared to that for the vehicle/DMXBA (a)- 
or vehicle/A-582941 (b) - group. +++p<0.001, significant reduction in DI compared to that 
for the PAM-2+DMXBA (a)- or PAM-2+A-582941 (b)-treated group.   
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Fig. 7: PAM-2 reverses the scopolamine-induced deficits in novel object recognition. 
PAM-2 (1.0 and 2.0 mg·kg-1) was administrated IP, followed 30 min later by IP 
administration of scopolamine (SCOP; 1.25 mg·kg-1). T1 (acquisition trial) was performed 30 
min after scopolamine administration, and T2 (retention trial) was performed 60 min after T1. 
Data are shown as the mean ± S.E.M. of discrimination index (DI) during T2. ***p<0.001, 
significant reduction in DI compared to that for the vehicle-treated group. ###p<0.001 and 
#p<0.05, significant increase in DI compared to that for the SCOP-treated group. 
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Fig. 8: PAM-2 enhances DMXBA-evoked α7 nAChR currents. 
SH-SY5Y-7 cells were initially treated with a fixed concentration of DMXBA (3 μM) (n = 
27), and the observed plateau current was considered the control (IDMXBA). To determine 
the potentiating effect of PAM-2, increasing concentrations of PAM-2 (1-300 μM; n = 4-8) 
were tested on the DMXBA-evoked 7 AChR currents (IPAM-2). The concentration-
response data were analysed by non-linear regression, according to Eq. (1). The results 
indicated that PAM-2 potentiates DMXBA-evoked 7 AChR currents with apparent EC50 = 
34 ± 3 μM, Emax = 225 ± 5 %, nH = 1.71 ± 0.23, and goodness of fit r2 = 0.997. 
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